

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

July 17, 2025

QUESTIONS

1. **DISCUSSION:** Discuss whether appropriate dosages of belantamab mafodotin have been identified for the proposed patient population with relapsed or refractory multiple myeloma.
2. **VOTE:** Is the overall benefit-risk of belantamab mafodotin in combination with bortezomib and dexamethasone favorable at the proposed dosage in the proposed patient population?
3. **VOTE:** Is the overall benefit-risk of belantamab mafodotin in combination with pomalidomide and dexamethasone favorable at the proposed dosage in the proposed patient population?